Novartis Ag (NVSEF) Total Debt (QoQ) (2009 - 2019)
Novartis Ag (NVSEF) Total Debt (QoQ) (2009 - 2019) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 8,249.41% |
| Mar 31, 2019 | -98.54% |
| Dec 31, 2017 | 29,995.00% |
| Sep 30, 2017 | 23.81% |
| Jun 30, 2017 | -19.32% |
| Mar 31, 2017 | -100.37% |
| Dec 31, 2016 | 15,456.13% |
| Sep 30, 2016 | 99.93% |
| Jun 30, 2016 | 27.34% |
| Mar 31, 2016 | -91,646.03% |
| Dec 31, 2015 | 99.89% |
| Mar 31, 2010 | -100.00% |
| Dec 31, 2009 | 61,026,877.66% |
| Sep 30, 2009 | -5.33% |
| Jun 30, 2009 | 31.79% |